This company has been marked as potentially delisted and may not be actively trading. Cesca Therapeutics (KOOL) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsDividendOwnershipTrendsBuy This Stock KOOL vs. THMO, IVVD, SPRO, BMEA, RCEL, SEER, CRBP, CNTB, QIPT, and MGNXShould you be buying Cesca Therapeutics stock or one of its competitors? The main competitors of Cesca Therapeutics include ThermoGenesis (THMO), Invivyd (IVVD), Spero Therapeutics (SPRO), Biomea Fusion (BMEA), Avita Medical (RCEL), Seer (SEER), Corbus Pharmaceuticals (CRBP), Connect Biopharma (CNTB), Quipt Home Medical (QIPT), and MacroGenics (MGNX). These companies are all part of the "medical" sector. Cesca Therapeutics vs. Its Competitors ThermoGenesis Invivyd Spero Therapeutics Biomea Fusion Avita Medical Seer Corbus Pharmaceuticals Connect Biopharma Quipt Home Medical MacroGenics Cesca Therapeutics (NASDAQ:KOOL) and ThermoGenesis (NASDAQ:THMO) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, valuation, media sentiment, analyst recommendations, dividends, earnings, institutional ownership and profitability. Which has more risk & volatility, KOOL or THMO? Cesca Therapeutics has a beta of 1.07, meaning that its stock price is 7% more volatile than the S&P 500. Comparatively, ThermoGenesis has a beta of 1.18, meaning that its stock price is 18% more volatile than the S&P 500. Is KOOL or THMO more profitable? ThermoGenesis has a net margin of 0.00% compared to Cesca Therapeutics' net margin of -98.84%. ThermoGenesis' return on equity of 0.00% beat Cesca Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Cesca Therapeutics-98.84% -77.30% -37.75% ThermoGenesis N/A N/A N/A Do insiders & institutionals have more ownership in KOOL or THMO? 3.1% of Cesca Therapeutics shares are owned by institutional investors. Comparatively, 5.8% of ThermoGenesis shares are owned by institutional investors. 68.9% of Cesca Therapeutics shares are owned by company insiders. Comparatively, 78.0% of ThermoGenesis shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Which has better earnings & valuation, KOOL or THMO? ThermoGenesis has lower revenue, but higher earnings than Cesca Therapeutics. Cesca Therapeutics is trading at a lower price-to-earnings ratio than ThermoGenesis, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCesca Therapeutics$9.67M3.12-$39.72M-$3.60-3.47ThermoGenesis$9.61M0.00-$17.98M-$5.14N/A Does the media favor KOOL or THMO? In the previous week, Cesca Therapeutics' average media sentiment score of 0.00 equaled ThermoGenesis'average media sentiment score. Company Overall Sentiment Cesca Therapeutics Neutral ThermoGenesis Neutral SummaryThermoGenesis beats Cesca Therapeutics on 8 of the 10 factors compared between the two stocks. Get Cesca Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for KOOL and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding KOOL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart KOOL vs. The Competition Export to ExcelMetricCesca TherapeuticsLaboratory Apparatus & Furniture IndustryMedical SectorNASDAQ ExchangeMarket Cap$30.21M$1K$5.86B$10.15BDividend Yield0.50%N/A5.68%4.59%P/E Ratio-3.47N/A74.5225.93Price / Sales3.120.00539.62123.65Price / CashN/AN/A37.5660.44Price / Book4.02N/A12.166.29Net Income-$39.72M-$17.98M$3.28B$270.77M Cesca Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)KOOLCesca TherapeuticsN/A$12.50+1.0%N/A+22.6%$30.21M$9.67M-3.4753THMOThermoGenesisN/AN/AN/AN/A$1K$9.61M0.0040IVVDInvivyd3.5243 of 5 stars$1.03+5.9%$3.18+209.1%+20.6%$116.90M$25.38M-1.12100Short Interest ↑SPROSpero Therapeutics4.3839 of 5 stars$2.05-1.0%$5.00+143.9%+45.5%$116.49M$47.98M-2.09150Positive NewsShort Interest ↓BMEABiomea Fusion3.5587 of 5 stars$2.03+4.1%$14.80+629.1%-73.8%$116.04MN/A-0.6750News CoveragePositive NewsRCELAvita Medical2.4453 of 5 stars$4.29-1.2%$12.40+189.0%-54.2%$115.53M$64.25M-2.18130SEERSeer0.717 of 5 stars$2.04-0.5%N/A+28.0%$115.50M$14.17M-1.47160CRBPCorbus Pharmaceuticals4.3909 of 5 stars$9.74+3.9%$49.00+403.1%-82.0%$114.83MN/A-2.0540Positive NewsCNTBConnect Biopharma3.8619 of 5 stars$2.11+2.4%$7.00+231.8%+29.4%$114.79M$26.03M0.00110Short Interest ↓QIPTQuipt Home Medical1.9125 of 5 stars$2.59-1.5%$3.15+21.6%-2.5%$114.26M$245.91M-10.791,200MGNXMacroGenics4.4735 of 5 stars$1.74-1.7%$3.60+106.9%-54.4%$111.87M$149.96M-3.05430Positive NewsHigh Trading Volume Related Companies and Tools Related Companies THMO Alternatives IVVD Alternatives SPRO Alternatives BMEA Alternatives RCEL Alternatives SEER Alternatives CRBP Alternatives CNTB Alternatives QIPT Alternatives MGNX Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:KOOL) was last updated on 9/12/2025 by MarketBeat.com Staff From Our PartnersForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredDo NOT Day Trade (Do THIS instead)Forget day trading (especially in markets like these). Trade OVERNIGHT instead! I've uncovered a shockin...Monument Traders Alliance | SponsoredCollege grad makes $64,000 a monthIt's easy to feel like you've missed out on the biggest stock market boom of the century. But if you want t...Stansberry Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredAlert: Prepare for Trump's Dollar OverhaulPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | SponsoredChina’s message to TrumpDid China just fire shots at America? Last week, in Tiananmen Square, China put on a chilling display of mi...Porter & Company | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cesca Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Cesca Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
